Berberine’s activation of AMPK triggers the ULK1 complex, initiating autophagy that can clear intracellular aggregates. During sleep, the glymphatic system convects cerebrospinal fluid through the brain parenchyma, extracting extracellular tau and other metabolites. We hypothesize that administering berberine at the onset of non‑rapid eye movement (NREM) sleep will amplify this nocturnal clearance by coupling AMPK‑driven autophagy with the glymphatic influx phase, while avoiding the synaptic loss seen with chronic AMPK hyper‑activation.

Mechanistically, AMPK phosphorylation of ULK1 not only promotes autophagosome formation but also upregulates aquaporin‑4 (AQP4) expression and its perivascular polarization, a key determinant of glymphatic efficiency. Simultaneously, berberine’s inhibition of PCSK9 lowers circulating LDL, reducing endothelial oxidative stress that can impair perivascular fluid channels. In microglia, transient AMPK activation shifts the phenotype toward a pro‑clearance state, decreasing cytokine‑mediated constriction of arterial pulsatility that drives glymphatic flow. Together, these effects create a time‑restricted window where extracellular waste is both autophagocytosed within cells and flushed via the glymphatic conduit.

Crucially, the dose‑dependent nature of AMPK signaling predicts a therapeutic window: low‑to‑moderate berberine concentrations (≈5–10 mg/kg in mice) activate AMPK sufficiently to enhance autophagy and AQP4 polarity without sustained activation that drives excessive synaptic pruning. High concentrations or continuous exposure would risk tipping the balance toward maladaptive autophagy, as shown in models of neuronal AMPK hyper‑activation leading to synapse loss.

Testable predictions:

1. Mice receiving berberine via timed oral gavage at ZT12 (lights‑off, onset of NREM) will show a 30‑40 % increase in CSF‑tracer influx compared with vehicle, measured by MRI‑based glymphatic imaging.
2. Concurrently, extracellular tau levels in the hippocampal interstitium will decline by ~25 % relative to controls, assessed by microdialysis and ELISA.
3. Synaptic density, quantified by synaptophysin immunostaining and electrophysiological LTP, will remain unchanged in the low‑dose group but significantly reduced in a high‑dose, continuously infused group.
4. Pharmacological blockade of AMPK (compound C) or ULK1 (MRT68921) administered before berberine will abolish the glymphatic enhancement, confirming pathway dependence.

This hypothesis links peripheral AMPK modulation to a central, sleep‑specific clearance mechanism, offering a falsifiable framework to determine whether circadian‑aligned berberine can bolster brain housekeeping without compromising synaptic integrity.